Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus

摘要: Hyperglycemia is the primary factor responsible for microvascular, and to a lesser extent macrovascular, complications of diabetes. Despite this well-established relationship, approximately half all type 2 diabetic patients in US have hemoglobin A1c (HbA1c) ≥7.0%. This associated part with side effects, i.e., weight gain hypoglycemia, currently available antidiabetic agents failure utilize medications that reverse basic pathophysiological defects present The kidney has been shown play central role development hyperglycemia by excessive production glucose throughout sleeping hours enhanced reabsorption filtered renal tubules secondary an increase threshold at which spills into urine. Recently, new class agents, sodium-glucose cotransporter (SGLT2) inhibitors, developed approved treatment In review, we examine their mechanism action, efficacy, safety, place therapeutic armamentarium. Since SGLT2 inhibitors unique mode action differs from other oral injectable they can be used stages disease combination medications.